Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5470 - Does melanoma or other skin cancers belong to the BRCA2 phenotype?

Date

10 Sep 2017

Session

Poster display session

Presenters

Rita Vitorino

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

R. Vitorino1, F. Vaz2, A.L. Carvalho3, S. Bento2, A. Luís2, A. Opinião3, A. Clara2, J. Dupont4, S. Santos5, P. Machado6, S. Fragoso5, P. Rodrigues4, J. Parreira4, C. Moura4

Author affiliations

  • 1 Medical Oncology, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 2 Familiar Cancer Risk Clinic, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 3 Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099 - Lisbon/PT
  • 4 Familiar Cancer Risk Clinic, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 5 Molecular Pathobiology Research Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 6 Molecular Pathobiology Investigation Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
More

Resources

Abstract 5470

Background

The BRCA2 phenotype includes breast (BC) and ovarian cancer (OC) as well as, less frequently, prostate (PC), gastric (GC) and pancreatic cancer. The association with melanoma remains unclear, because previous studies were retrospective and included non- confirmed carriers. With this study we intend to determine the rate of melanoma and nonmelanoma skin cancers diagnoses in a consecutive prospective cohort of confirmed BRCA2 carriers.

Methods

Review of all skin cancer diagnoses in BRCA2 carriers under prospective surveillance.

Results

Four hundred and eighty six BRCA2 carriers (376 female, 110 male) belonging to 216 families were identified. The median age for genetic diagnosis was 48,3yrs with the BRCA2 c.156_157inAlu being the mutation most frequently observed (43,6%). Most carriers (359/486) had yearly full skin examinations. Although a majority of women (226/376) were cancer survivors (209 BC, 29 OC and 12 with breast/ovarian cancer), only 30/110 men had a previous cancer diagnosis (20 BC, 8 PC and 2 GCs). For a median follow up of 4 yrs, melanoma diagnoses were 3 in 2 female with bilateral BC. The patient with 2 melanomas had the first melanoma at 28yrs before BC diagnoses. Other skin cancers: 14 squamous cell carcinoma (SCC) (8 invasive, 6 in situ SCC) and 14 pts with basal cell carcinoma (BCC), 6 of which with multiple BCC. Four pts were diagnosed with actinic keratosis (AK). The rate for melanoma is 0,4% and for nonmelanoma skin cancers 5%. The rate for skin cancer in BRCA2 carriers with a previous cancer diagnosis is 2%. No statistical significance was found either for the association of skin cancer (p = 0,221) or melanoma (p = 0,9) with specific BRCA2 mutations.

Conclusions

The low rates of melanoma diagnosis in our prospective confirmed BRCA2 cohort, raises questions about the previously described association of melanoma and BRCA2 mutations. Also, no association was found between the Portuguese founder mutation and melanoma or other skin cancers. Although more follow up may be needed, there is insufficient evidence to warrant increased skin surveillance of BRCA2 carriers in the absence of standard skin cancer risk factors.

Clinical trial identification

Legal entity responsible for the study

IPOL FG, E.P.E.

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.